Market Place
Sourcing Support
Kymera Therapeutics Reveals Q1 2026 Financials And Business
30 Apr 2026 //
GLOBENEWSWIRE
Kymera Therapeutics To Release Q1 2026 Financial Results
23 Apr 2026 //
GLOBENEWSWIRE
Kymera Pharma`s KT-621, Granted FDA Fast Track For Severe Asthma
13 Apr 2026 //
GLOBENEWSWIRE
Kymera Announces Gilead’ Option Exercise to License KT-200
10 Apr 2026 //
ENDPOINTS NEWS
Gilead Exercises Kymera`s KT-200 Option
09 Apr 2026 //
GLOBENEWSWIRE
Gilead Pays Kymera $45M For Preclinical Protein Degrader
09 Apr 2026 //
FIERCE BIOTECH
Kymera Therapeutics Presents KT-621 Broaden Data at AAD
28 Mar 2026 //
GLOBENEWSWIRE
Kymera`s Late-Breaking Oral Presentation on KT-621 at AAD Meeting
10 Mar 2026 //
GLOBENEWSWIRE
Kymera Therapeutics Joins March Investor Conferences
24 Feb 2026 //
GLOBENEWSWIRE
Kymera Therapeutics Reports Q4 & FY 2025 Financial Results
19 Feb 2026 //
GLOBENEWSWIRE
Kymera Therapeutics Joins February Investor Conferences
04 Feb 2026 //
GLOBENEWSWIRE
Kymera Doses First Patient in BREADTH KT-621 Trial
29 Jan 2026 //
GLOBENEWSWIRE
Kymera Therapeutics Outlines 2026 Immunology Strategy
13 Jan 2026 //
GLOBENEWSWIRE
Kymera Therapeutics To Present At J.P. Morgan Healthcare Conf
06 Jan 2026 //
GLOBENEWSWIRE
FDA Grants Fast Track to Kymera`s KT-621 for Atopic Dermatitis
11 Dec 2025 //
GLOBENEWSWIRE
Kymera Closes $602M Offering With Full Option Exercise
11 Dec 2025 //
GLOBENEWSWIRE
Kymera Reports Positive Results In KT-621, Phase 1B Trial
08 Dec 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Proposed Public Offering
08 Dec 2025 //
GLOBENEWSWIRE
Kymera Unveils KT-621 BroADen Ph1b Atopic Dermatitis Results
05 Dec 2025 //
GLOBENEWSWIRE
Kymera Launches BROADEN-2 Phase 2b Trial for Atopic Dermatitis
25 Nov 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Joins December Investor Conferences
24 Nov 2025 //
GLOBENEWSWIRE
Kymera Therapeutics to Release Q3 2025 Financial Results on Nov 4
28 Oct 2025 //
GLOBENEWSWIRE
Kymera Unveils Preclinical Data on KT-579, at ACR Meeting
27 Oct 2025 //
GLOBENEWSWIRE
Kymera Announces Late-Breaking Oral Presentations on KT-621
17 Sep 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Names Brian Adams Chief Legal Officer
03 Sep 2025 //
GLOBENEWSWIRE
Kymera Therapeutics to Present at September Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
Kymera Reports Q2 2025 Financial Results and Business Update
11 Aug 2025 //
GLOBENEWSWIRE
Kymera Therapeutics to Announce Q2 2025 Financial Results
04 Aug 2025 //
GLOBENEWSWIRE
Gilead Signs up to $750 Million Cancer Drug Deal with Kymera
27 Jun 2025 //
PRESS RELEASE
Kymera Therapeutics Announces Pricing of $250M Public Offering
26 Jun 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Proposed Public Offering
25 Jun 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
25 Jun 2025 //
PRESS RELEASE
Kymera Therapeutics Reports Positive Phase 1 Results for KT-621
02 Jun 2025 //
GLOBENEWSWIRE
Kymera Therapeutics to Announce KT-621 Phase 1 Trial Results
30 May 2025 //
GLOBENEWSWIRE
Kymera Therapeutics to Join June Investor Conferences
29 May 2025 //
GLOBENEWSWIRE
Kymera Presents STAT6 Degrader KT-621 Data at ATS
19 May 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Reports Q1 2025 Results and Business Update
09 May 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Expands Immunology Pipeline with New Oral IRF
09 May 2025 //
GLOBENEWSWIRE
Kymera Therapeutics in Fireside Chat at BofA Securities 2025 Conf
07 May 2025 //
GLOBENEWSWIRE
Kymera to Unveil New Oral Immunology Program & Q1 Result
24 Apr 2025 //
GLOBENEWSWIRE
Kymera Therapeutics: 1st Patient Dosed in Ph 1b Atopic Dermatitis
22 Apr 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Names Noah Goodman Chief Business Officer
09 Apr 2025 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Q4 and Full Year 2024 Results
27 Feb 2025 //
GLOBENEWSWIRE
Kymera Therapeutics to Join March Investor Conferences
26 Feb 2025 //
GLOBENEWSWIRE
Kymera To Release Q4, Full-Year 2024 Results On Feb 27
20 Feb 2025 //
GLOBENEWSWIRE
Kymera Therapeutics to Participate in February Investor Conferences
30 Jan 2025 //
GLOBENEWSWIRE
Kymera Shares 2025 Plan to Advance Oral Immunology Program
14 Jan 2025 //
GLOBENEWSWIRE
Kymera Therapeutics to Present at 43rd J.P. Morgan Conference
07 Jan 2025 //
GLOBENEWSWIRE
Kymera to Participate in Upcoming December Investor Conferences
26 Nov 2024 //
GLOBENEWSWIRE
Kymera Therapeutics to Participate in Nov Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Kymera pivots to immunology, seeks partners for cancer assets
04 Nov 2024 //
FIERCE BIOTECH
Kymera Therapeutics Reports Q3 2024 Results & Business Update
31 Oct 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Reports Q3 2024 Financial Results
31 Oct 2024 //
GLOBENEWSWIRE
Kymera Doses First Participant In KT-621 Phase 1 Trial
24 Oct 2024 //
GLOBENEWSWIRE
Kymera Announces Three Presentations at EORTC-NCI-AACR
23 Oct 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Q3 2024 Financial Results on October 31
23 Oct 2024 //
GLOBENEWSWIRE
Kymera Announces FDA Clearance Of IND For KT-621
09 Oct 2024 //
GLOBENEWSWIRE
Kymera Presents KT-621 Preclinical Data At EADV Congress
25 Sep 2024 //
GLOBENEWSWIRE
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Closes $225M Public Offering With Full Option Exercise
21 Aug 2024 //
GLOBENEWSWIRE
